Torthaí cuardaigh - José Garnacho‐Montero
- 1 - 20 toradh as 55 á dtaispeáint
- Téigh chuig an gcéad leathanach eile
-
1
Approach to invasive pulmonary aspergillosis in critically ill patients de réir Despoina Koulenti, José Garnacho‐Montero, Stijn Blot
Foilsithe / Cruthaithe 2014Revisão -
2
Antibiotic de-escalation in the ICU de réir José Garnacho‐Montero, Ana Escoresca‐Ortega, Esperanza Fernández-Delgado
Foilsithe / Cruthaithe 2015Revisão -
3
Fungal infections in immunocompromised critically ill patients de réir José Garnacho‐Montero, Irene Barrero-García, Cristina León-Moya
Foilsithe / Cruthaithe 2024Revisão -
4
-
5
Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality de réir José Garnacho‐Montero, Antonio Gutiérrez‐Pizarraya, Ana Escoresca‐Ortega, Esperanza Fernández-Delgado, José María López-Sánchez
Foilsithe / Cruthaithe 2015Artigo -
6
Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. de réir José Garnacho‐Montero, T. Aldabó-Pallás, Carmen Garnacho, Aurelio Cayuela, R. Jiménez, Sónia Barroso, Carlos Ortíz-Leyba
Foilsithe / Cruthaithe 2006Artigo -
7
Timing of antibiotic therapy in the ICU de réir Marin H. Kollef, Andrew F. Shorr, Matteo Bassetti, Jean‐François Timsit, Scott T. Micek, Andrew P. Michelson, José Garnacho‐Montero
Foilsithe / Cruthaithe 2021Revisão -
8
Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease de réir Rosario Amaya-Villar, José Garnacho‐Montero, J.L. García Garmendia, Juan Madrazo-Osuna, Carmen Garnacho, Rafael Luque, Carlos Ortíz-Leyba
Foilsithe / Cruthaithe 2004Artigo -
9
Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain de réir David L. Suarez, Ricard Ferrer, Antonio Artigas, I. Azkárate, José Garnacho‐Montero, Gemma Gomà, Mitchell M. Levy, Juan Carlos Ruiz
Foilsithe / Cruthaithe 2010Artigo -
10
Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients de réir Ricard Ferrer, Xavier Mateu, Emilio Maseda, Juan Carlos Yébenes, César Aldecoa, Candelaria de Haro, Juan Carlos Ruiz‐Rodríguez, José Garnacho‐Montero
Foilsithe / Cruthaithe 2017Revisão -
11
Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. de réir José Garnacho‐Montero, Rosario Amaya-Villar, Carlos Ortíz-Leyba, Cristóbal León, Francisco Álvarez-Lerma, Juan Nolla‐Salas, José Ramón Iruretagoyena, Fernando Barroso-Barcenilla
Foilsithe / Cruthaithe 2005Artigo -
12
Risk Factors for<i>Acinetobacter baumannii</i>Nosocomial Bacteremia in Critically Ill Patients: A Cohort Study de réir J.L. García Garmendia, Carlos Ortíz-Leyba, José Garnacho‐Montero, F. J. Jiménez-Jiménez, C. Pérez-Paredes, A Barrero-Almodóvar, Miguel Gili‐Miner
Foilsithe / Cruthaithe 2001Artigo -
13
Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings de réir José Garnacho‐Montero, Carlos Ortíz-Leyba, Esteban Fernández-Hinojosa, T. Aldabó-Pallás, Aurelio Cayuela, Juan Antonio Márquez-Vácaro, A. García-Curiel, F. J. Jiménez-Jiménez
Foilsithe / Cruthaithe 2005Artigo -
14
Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia de réir Jordi Rello, Alejandro Rodríguez, Antoni Torres, Jorge Roig, Jordi Solé‐Violán, José Garnacho‐Montero, M. V. de la Torre, Josep Maria Sirvent, María Bodí
Foilsithe / Cruthaithe 2006Artigo -
15
The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acineto... de réir T. Amat, Antonio Gutiérrez‐Pizarraya, Isabel Machuca, Irene Gracia-Ahufinger, Elena Pérez‐Nadales, Á. Torre‐Giménez, José Garnacho‐Montero, José Miguel Cisneros, Julián Torre‐Cisneros
Foilsithe / Cruthaithe 2017Artigo -
16
Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study de réir José Garnacho‐Montero, Carlos Ortíz-Leyba, Inmaculada Concepción Herrera-Melero, T. Aldabó-Pallás, Aurelio Cayuela, Juan Antonio Márquez-Vácaro, J. Carbajal-Guerrero, J.L. García Garmendia
Foilsithe / Cruthaithe 2007Artigo -
17
Risk Factors for Fluconazole-Resistant Candidemia de réir José Garnacho‐Montero, Ana Díaz‐Martín, Emilio García-Cabrera, Maite Ruiz Pérez de Pipaón, C Hernandez-Caballero, Javier Aznar, José Miguel Cisneros, Carlos Ortíz-Leyba
Foilsithe / Cruthaithe 2010Artigo -
18
Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis de réir José Garnacho‐Montero, María J Huici-Moreno, Antonio Gutiérrez‐Pizarraya, Isabel López, Juan Antonio Márquez-Vácaro, Hada C. Macher, Juan M. Guerrero, Antonio Puppo-Moreno
Foilsithe / Cruthaithe 2014Artigo -
19
European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria de réir Alain Lepape, Astrid Jean, Jan J. De Waele, Arnaud Friggeri, Anne Savey, Philippe Vanhems, Marie Paule Gustin, Dominique L Monnet, José Garnacho‐Montero, Anke Kohlenberg
Foilsithe / Cruthaithe 2020Artigo -
20
Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients de réir José Garnacho‐Montero, Juan Madrazo-Osuna, J.L. García Garmendia, Carlos Ortíz-Leyba, F. J. Jiménez-Jiménez, A Barrero-Almodóvar, Carmen Garnacho, M. Moyano-Del-Estad
Foilsithe / Cruthaithe 2001Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Medicine
Internal medicine
Intensive care medicine
Biology
Microbiology
Antibiotics
Intensive care unit
Sepsis
Pneumonia
Intensive care
Emergency medicine
Antibiotic resistance
Critically ill
Genetics
Bacteria
Cohort study
Immunology
Cohort
Pseudomonas aeruginosa
Acinetobacter baumannii
Pathology
Prospective cohort study
Septic shock
Antimicrobial
Disease
Anesthesiology
Antifungal
Colistin
Confidence interval
Coronavirus disease 2019 (COVID-19)